Details for Patent: 11,564,917
✉ Email this page to a colleague
Which drugs does patent 11,564,917 protect, and when does it expire?
Patent 11,564,917 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.
Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-one patent family members in twenty-three countries.
Recent additions to Drugs Protected by US Patent 11,564,917
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Feb 17, 2023 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Jul 1, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | May 29, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | May 29, 2024 | RX | No | ⤷ Sign Up | ⤷ Sign Up | U-1995 | TREATMENT OF TARDIVE DYSKINESIA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,564,917
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-008 | Jul 1, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-003 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-004 | May 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-005 | May 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-006 | May 29, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,564,917
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 103876 | ⤷ Sign Up | |||
| Australia | 2016229949 | ⤷ Sign Up | |||
| Australia | 2021204740 | ⤷ Sign Up | |||
| Canada | 2978006 | ⤷ Sign Up | |||
| Chile | 2017002223 | ⤷ Sign Up | |||
| China | 107624067 | ⤷ Sign Up | |||
| China | 114767672 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
